757 Angels and ivWatch Reach Entrepreneurs at Tom Tom Fest

Local business leaders invited to speak at 7th Annual Tom Tom Founders Festival

CHARLOTTESVILLE, Va., April 16, 2018 – 757 Angels and ivWatch recently collaborated during an entrepreneurship session at Tom Tom Founders Festival, a week-long celebration of innovators, visionaries and artists who shape small cities. Part pitch competition, part case study – the organizations co-presented and provided insight into building and growing successful companies and how to foster the next generation of innovators in tech industries.

The session “An Empirical View of the Art and Science of Entrepreneurship and Investment,” was hosted by representatives from the Center for Innovative Technology’s (CIT) GAP Fund on Thursday, April 12. The Hampton Roads entrepreneur community was represented by Monique Adams, executive director of 757 Angels, a group whose membership consists of business and community leaders and Gary Warren, president and CEO of ivWatch, a medical device manufacturer and biosensor technology company. Both shared perspectives from investor and business leader sides of the table.

When asked by session panel member Jayson Rieger, a principle of the PBM Capital Group, about 757 Angels satisfaction with their investment in ivWatch, Adams responded, “ivWatch had incredible momentum early on, and they’ve sustained their competitive advantage. We are extremely pleased with our relationship.”

Virginia Secretary of Commerce and Trade, Esther Lee, opened the event with an announcement of the Virginia Founders Fund, a new seed-stage fund that increases access to venture capital in Virginia. In her comments, she emphasized the ability for software, hardware, life science, cleantech, and technology-enabled services companies to generate economic returns for the Commonwealth.

During his time on stage, Warren touched on the growth and scaling of ivWatch. “Each year we put together an update of the business plan, and we’ve been successful in the execution of our goals. A focus this year is bringing more manufacturing in-house to control quality, cost and bring more high-tech jobs to the area.”

The event brought together regional angel investor and funding groups, including 757 Angels, CIT Gap Fund, Charlottesville Angel Network, and The Launch Place, who each brought one of their most exceptional startups or emerging growth companies they’ve supported. The event focused on the dynamics between the groups and how individual successes support the statewide initiatives outlined by Secretary Lee.

To learn more about ivWatch, visit www.ivWatch.com. To learn more about 757 Angels, visit www.757angelsgroup.com.

About 757 Angels:
757 Angels is a select network of over 100 business and community leaders in the Hampton Roads region, who provide investment capital, strategic advice and mentoring to selected startup and early-stage companies to help them achieve market leadership. 757 Angels seeks dealflow from the Commonwealth of Virginia.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivwatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

In the News: I’m an Engineer, But I Can’t Fix Stupid

ivWatch’s Gary Warren Discusses Future of Healthcare and Device Development in MD+DI
ivWatch President and CEO, Gary Warren, offers his insights on device development and non-traditional human factors in the Medical Device and Diagnostic Industry (MD+DI) article, “I’m an Engineer, But I Can’t Fix Stupid.” In the piece, Warren reflects on his career experiences in other industries and why they shaped his philosophy around medical device development. The article focuses on the consumer power evolution in healthcare, and why companies like ivWatch must be at the forefront of interpreting consumer needs to set the standards for the medical device industry’s future. Read the full article here.

In the News: ivWatch Detects IV Infiltrations and Extravasations

Medgadget Interviews CEO of ivWatch
The editors at Medgadget set the stage for an interview with Gary Warren, president and CEO of ivWatch, by reviewing many of the recent company milestones; FDA clearances, patent grants, manufacturing operations and world-class customers. Within the interview, Warren explains the IV infiltration landscape and the company’s mission to improve the level of quality and patient safety through early detection of these events. The interview goes on to discuss at-risk patient populations, innovative hospitals who are champions for IV assessment improvement, and the need for greater awareness of the risks associated with the procedure. The interview concludes by touching on the science behind ivWatch biosensor technology and the efforts the company is making to set the new standard of care for IV therapy. Read the full interview here.

In the News: ivWatch is anchor tenant at Tech Center Research Park in Newport News

Advancement of Region’s Tech Community Covered by Inside Business

ivWatch’s commitment to becoming the anchor tenant of Tech Center Research Park was covered recently in Inside Business. The article discusses the how the synergy between ivWatch departments and new tenants will inspire an evolution of the technology sector in Hampton Roads. ivWatch President and CEO Gary Warren discusses the attractive amenities of the space to retain and recruit employees and successfully execute the company’s business plan, where the Park’s Director, Jeff Johnson, says ivWatch will be a key driver in creating an innovative environment by attracting other high-tech operations to the area. Read the full article here.

ivWatch Announces Relocation Commitment to Accommodate Growth


Tech Center Research Park welcomes medical device company as anchor tenant

NEWPORT NEWS, Va., March 6, 2018 – ivWatch, the only provider of medical devices for the early detection of intravenous (IV) infiltrations and extravasations, announced today that it is moving forward with plans to relocate from their Hampton and Williamsburg facilities to anchor Newport News Tech Center Research Park‘s Building One. The move will increase operational efficiency by combining all departments, including manufacturing and research and development, under one roof.

“We are experiencing continued growth year after year in staff size, sales and manufacturing operations,” said Gary Warren, president and CEO of ivWatch. “The decision to move to the Research Park supports the execution of our business and recruiting plans. Within the next four years, we plan to add 150 new employees to support our international market-entry and expanding our sales activity in the U.S. through two leading healthcare group purchasing organization(GPO) contracts.”

The company has made substantial progress in developing, designing and commercializing a pioneering non-invasive biosensor technology. Terumo Corporation, one of the world’s leading medical device manufacturers and distributors, was recently named the exclusive distributor for ivWatch in Japan. Additionally, through “Breakthrough” and “Innovative” technology group purchasing contract awards from Premier and Vizient, the ivWatch Model 400 is more accessible to thousands of hospitals and healthcare systems across the U.S.

The Newport News Tech Center will be home to more than one million square feet of space across 11 planned buildings, punctuated by restaurants, shops, fitness clubs, biking trails and gathering spots. With a highly-skilled workforce, the addition of ivWatch to the Research Park will help foster and fuel the technology sector in the Hampton Roads area.

The new headquarter building is part of ivWatch’s investment in supporting their growing operations and customer base as well as the community.

“The best companies are those with access to research, influence and partners with resources you don’t have yet. As a young company in the medical device market, it’s essential to develop and pursue those types of resources to build a company in this tightly regulated industry,” said Warren. “We are proud of the success we’ve achieved, and this workplace will allow us to provide access to others by sharing our journey of how we turned research and data into a solution-based application used in leading hospitals across the country.”

Master building plans include prominent ivWatch signage on the exterior of the building, with ivWatch occupying more than 25,500 sq. ft. including manufacturing, warehouse space on the first floor, and state-of-the-art office space on the first and third floors. The company will keep their open floor plan concept which they’ve found facilitates interdepartmental collaboration. The building will include space for other tenants, co-working spaces and a business accelerator program.

The construction of the building is underway, with a target move-in date of late 2018.

To learn more about ivWatch, visit www.ivWatch.com. To learn more about Tech Center Research Park, visit innovateattechcenterva.com.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivWatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

In the News: Expected Tech Center Anchor to Add 150 Jobs

New Headquarters and Planned Growth Featured in Daily Press and TidewaterBiz
The ivWatch commitment to a new headquarter building at Newport News Tech Center was covered in the Daily Press and TidewaterBiz article, “Expected Tech Center Anchor to Add 150 Jobs.” The announcement includes the company becoming the anchor tenant of the first building of the corporate research park, and ivWatch’s growth and recruitment plans over the next four years. ivWatch President and CEO Gary Warren discusses the demand for the company’s technology from recent contracts and partnerships and bringing visibility to tech talent in Hampton Roads. Read the full article here.

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest